Article Topic
October 15, 2025: A JAMA study promotes med spa regulation; a new documentary explores fake GLP-1s
A study says IV hydration spas need more oversight. Louisiana residents were hospitalized after receiving black market botulinum toxin injections. Hulu delved into the counterfeit GLP-1 market and Fierce Healthcare covered AFPs.
[...]Oregon State Pharmacy Association makes the case for PBM reform, not payment limits
This summer, Brian Mayo, Executive Director of the Oregon State Pharmacy Association (OSPA), made the case for pharmacy benefit manager (PBM) reform as a better way to rein in drug prices.
[...]Case overview, Gilead Sciences v Meritain Health, et al
Gilead Sciences filed a Lanham Act complaint against a group of companies that allegedly pushed patients into ordering non-FDA approved international medicines to lower costs in employer-sponsored health insurance plans.
[...]Why are price cap proposals on medicines dangerous to pharmacies and patients?
Supply chain complexity means that upper payment limits and Medicare maximum fair prices will fall disproportionately on pharmacies, leading to closures that threaten patient access to care.
[...]Med spas need stronger regulation
Medical spas and wellness clinics are operating on the edge of existing regulatory frameworks and it’s a risk to American patients.
[...]Prescription Drug Affordability Board Activity, August 2025
Prescription Drug Affordability Board Activity, August 2025 Activities Summary Colorado: Colorado’s PDAB met on August 22, 2025 for to continue rulemaking to set an upper payment limit for Enbrel, during which they heard substantial public comment. They will continue this process at their next meeting on October 3. Maryland: The next PDAB meeting will be…
[...]September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA
The warning letter was one of about 100 is a new focus on deceptive direct-to-consumer drug advertisements.
[...]September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers
The “green list” will help protect patients from unreliable, illegally compounded GLP-1s and simplify screening for border security.
[...]PSM leads letter in support of an FDA mandate to destroy high-risk imports
PSM led a coalition of organizations urging leaders of the Senate HELP and House Energy and Commerce committees to help strengthen the FDA’s ability to protect Americans from unsafe and counterfeit medicines and medical products.
[...]10 years of fentanyl pills
A decade ago no one had heard of deadly counterfeit prescription pills. Victims’ families bravely spoke up, lobbied, and rallied for change.
[...]